Objective: To construct and analyze a database comprised of all reported cases of primary breast lymphoma (PBL) that include treatment and follow-up information published during the last 3 decades. Summary Background Data: PBL accounts for 0.4% of breast malignancies and 2% of extranodal lymphomas. Surgical therapy has varied from biopsy to radical mastectomy. Chemotherapy and radiation therapy have been used as adjuvant or primary therapy. A standard consensus treatment of PBL is not available. Methods: We reviewed all published PBL reports from June 1972 to March 2005. A database was compiled by abstracting individual patient information, limiting our study to those reports that contained specific treatment and outcome data. Patient demographics such as survival, recurrence, and time to follow-up were recorded, in addition to surgical, radiation, and/or chemotherapy treatment(s). Results: We found 465 acceptable patients reported in 92 publications. Age range was 17 to 95 years (mean, 54 years). Mean tumor size was 3.5 cm. Diffuse large cell (B) lymphoma was the most common histologic diagnosis (53%). Disease-free survival was 44.5% overall. Follow-up ranged from one to 288 months (mean, 48 months). Treatment by mastectomy offered no survival benefit or protection from recurrence. Treatment that included radiation therapy in stage I patients (node negative) showed benefit in both survival and recurrence rates. Treatment that included chemotherapy in stage II patients (node positive) showed benefit in both survival and recurrence rates. Histologic tumor grade predicted survival. Conclusions: Mastectomy offers no benefit in the treatment of PBL. Nodal status predicts outcome and guides optimal use of radiation and chemotherapy. (Ann Surg 2007;245: 784 -789) P rimary breast lymphoma (PBL) represents 2.2% of ex-From the
tranodal lymphomas and accounts for less than 0.5% of breast malignancies. 1, 2 Although the origin of the lymphocytes within the breast giving rise to lymphoma is unclear, these tumors may arise from mucosal-associated lymphoid tissue (MALT). 1 PBL might also originate in lymphatic tissue present within the breast adjacent to ducts and lobules, or from intramammary lymph nodes. 3, 4 Surgery, radiation, and chemotherapy have been used alone or in combination in treatment of PBL. No clear consensus for therapy has emerged, although chemotherapy seems to be the more common choice, alone or in combination with other treatments. Prognosis and effectiveness of individual treatments are generally extrapolated from therapy for other extranodal lymphomas. Although chemotherapy has become the mainstay of treatment of extranodal lymphomas in general, mastectomy has been a common component of PBL therapy for decades and remains a frequent treatment choice in some reports.
The diagnostic criteria for PBL, described by Wiseman and Liao, 5 remains the standard definition for this disease. As no specific pathologic features separate breast from other extranodal sites of lymphoma, the Wiseman and Liao definition appears to be best suited in evaluation and specifically targeting treatment of this tumor site. The specific criteria for the diagnosis of PBL include:
1. The clinical site of presentation is the breast. 2. A history of previous lymphoma or evidence of widespread disease are absent at diagnosis. 3. Lymphoma is demonstrated with close association to breast tissue in the pathologic specimen. 4. Ipsilateral lymph nodes may be involved if they develop simultaneously with the primary breast tumor.
This definition of PBL comprises only tumors that are stage I (lymphoma limited to the breast) and stage II (lymphoma limited to the breast and axillary lymph nodes), excluding those tumors that may have originated at nonbreast sites.
Our goal was to construct and analyze a database comprised of all reported cases of PBL during the last 34 years, where patient-specific treatment and follow-up information were included, to determine the best treatment strategies for PBL. 
METHODS

RESULTS
Patient Demographics
A total of 465 individual patients met the criteria for inclusion. Age range was 17 to 95 years (mean, 54 years). A total of 307 individuals had single tumors with tumor size specified (mean, 3.5 cm). The right breast was the tumor site in 50.4% of these patients. Bilateral tumors were found in 35 patients. Diffuse large cell (B) lymphoma was the most common histologic diagnosis (53%). Disease-free survival was 44.5% overall. 10.8% of patients were alive with metastatic disease. Follow-up ranged from 1 to 288 months, with a mean of 48 months. Using the Wiseman and Liao definition of PBL, 44.6% were stage I and 28.3% were stage II. Axillary lymph node status was not specified in the remaining 27.1%.
Analysis of Individual Treatment Selection
Mastectomy was used alone or in combination with other therapy in 156 patients. Simple mastectomy was used in 65 patients, while 62 individuals had a modified radical mastectomy, and 29 patients underwent a radical mastectomy. Chemotherapy was used in 323 individuals and specified as CHOP (cyclophosphamide, hydroxydoxorubicin, oncovin, and prednisone) in 103 of these patients. Radiation therapy was reported in 218 patients.
Patients older than the mean age were more likely to receive radiation therapy (P ϭ 0.01) and to be treated by mastectomy (P ϭ 0.15). In patients with tumors larger than the mean size (3.5 cm), mastectomy was more common (P ϭ 0.001). Chemotherapy was also more commonly used in patients with larger tumors (P ϭ 0.002); however, no relation to tumor size was found in the selection of radiation treatment. Patients with larger tumors were more likely to have lymph node metastases (P ϭ 0.01).
Neither treatment with radiation therapy or mastectomy was found to correlate with lymph node status, although chemotherapy was more likely given in patients with positive nodes (P ϭ 0.001).
Patients treated without mastectomy were more likely to receive radiation therapy (P ϭ 0.01). Those patients treated without mastectomy had a trend to receive chemotherapy more commonly than mastectomy patients (P ϭ 0.05). Combined use of chemotherapy and radiation therapy appeared less likely than expected if selections were made independently (P ϭ 0.001), suggesting a bias against the combination of treatments.
Outcomes
Node status, age, histology (high, intermediate, and low grade), and tumor size were evaluated for survival and recurrence risk. In addition, survival was evaluated for cases published before and after 1995. Age and date of publication were the only factors found not to have a significant association with survival. Disease-free survival was 44.5% overall. No survival difference was observed between patients reported in articles published before or after 1995.
Evaluating all patients without regard to node status or tumor size, a trend toward lower survival rate was found in patients treated by mastectomy ( Fig. 1 ). Both all-cause mortality and disease-specific mortality rates were higher when treatment involved mastectomy (P ϭ 0.055).
We found patients treated by mastectomy were less likely to receive chemotherapy and/or radiation therapy (P ϭ 0.015). While subgroup analysis of mastectomy patients receiving other treatments found reduced sample sizes and resulted in larger P values, the difference in hazard ratios remained approximately the same, suggesting that the smaller number of mastectomy patients receiving additional therapy was not an explanation of the observed difference in survival. Mastectomy subjects had larger tumors at presentation (mean size was 0.97 cm greater than other treatment groups), but this difference was accounted for in patients with tumors smaller than the mean size of 3.5 cm. Regardless, a Cox regression analysis indicated an increased survival risk for mastectomy patients even after adjusting for tumor size.
Analyzing all patients, a trend toward overall survival benefit was noted in those individuals treated with radiation therapy. Those individuals receiving radiation therapy had a 47.9% survival versus 37.1% survival in individuals not receiving radiation therapy (P ϭ 0.07).
A Cox regression model analyzing tumor size and node status revealed that node status was the best single predictor of survival. After adjustment for node status, tumor size was not significant. Another Cox regression survival analysis was FIGURE 1. Survival curves for all patients with treatment that included mastectomy (n ϭ 152) versus all patients treated without mastectomy (n ϭ 297).
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Primary Breast Lymphoma used with variables for mastectomy, radiation, chemotherapy, and node status for prediction of survival. To be included, a subject had to have had complete data for all variables used. There were 305 evaluable subjects for analysis. Fourteen individuals who did not have a mastectomy, radiation, or chemotherapy were excluded. The Cox analysis revealed significant interaction of treatment modalities and node status; therefore, analyses were done within each node status subgroup. There was significant evidence of the efficacy of radiation therapy in node-negative patients (P ϭ 0.002; hazard ratio ϭ 2.42), indicating that patients not receiving radiation therapy are at more than twice the risk of death. Figure 2 demonstrates survival curves according to treatment of individuals with negative lymph node status (stage I). This analysis also identified treatment with chemotherapy in nodepositive patients to have a significant survival benefit (P ϭ 0.001; hazard ratio ϭ 3.04). Figure 3 demonstrates survival by treatment of individuals with positive lymph node status (stage II). Data regarding combined radiation and chemotherapy were equivocal due to small sample sizes, but together they likely had the same survival and recurrence advantages as single treatment options in appropriate node status groups. The importance of lymph node status on PBL treatment selection is emphasized by the analysis of data without regard to positive or negative lymph node status. Analysis of all patients by treatment alone finds no significant difference in outcome by treatment groups. Node-negative patients treated by mastectomy (n ϭ 67) received radiation therapy 31.3% of the time, while 64.2% of node-negative patients treated without mastectomy (n ϭ 120) received radiation therapy (P ϭ 0.0001). In node-positive patients undergoing mastectomy, 75.8% received chemotherapy while 91.8% of node-positive patients treated without mastectomy received chemotherapy (P ϭ 0.019). Assuming the importance of radiation therapy and chemotherapy to particular subgroups (stage I and stage II patients, respectively), one might suspect that this would account for the apparent poor survival for patients treated by mastectomy in the initial analysis of all patients based on treatment alone. We therefore reevaluated the patients with known node status for survival analysis with mastectomy. This treatment analysis included radiation therapy with or without mastectomy in node-negative patients and chemotherapy with or without mastectomy in node-positive patients. In these patients with known node status and presumed appropriate adjuvant therapy according to stage, there was no survival benefit offered by mastectomy ( Fig. 4 ).
Outcome analysis for mastectomy patients (simple mastectomy ͓n ϭ 65͔, modified radical mastectomy ͓n ϭ 62͔, or radical mastectomy ͓n ϭ 29͔ found no survival difference related to type of mastectomy in either stage I or stage II patients.
Recurrence
Recurrence information was available in 320 patients. A Cox regression model was obtained for recurrence analysis with 3 treatment modalities (chemotherapy, radiation, and mastectomy) as predictor variables (n ϭ 303). Mastectomy did not offer protection from recurrence for either stage I or stage II patients. Stage I patients receiving radiation (n ϭ 85) with or without the addition of chemotherapy had a lower risk of recurrence (P ϭ 0.037) than patients receiving chemotherapy alone (n ϭ 54). Stage II patients receiving chemotherapy (n ϭ 76) with or without the addition of radiation were at a lower risk for recurrence (P ϭ 0.0001) than patients receiving radiation alone (n ϭ 10).
Recurrence risk was also related to tumor size. Patients with tumors smaller than the mean (3.5 cm) had reduced recurrence risk if treatment included radiation therapy (P ϭ 0.049; hazard ratio ϭ 2.49). Patients with tumors larger than 3.5 cm had a lower recurrence risk if chemotherapy was given (P ϭ 0.028; hazard ratio ϭ 2.49).
Data regarding combined radiation and chemotherapy were equivocal due to small sample sizes, but together they likely had the same survival and recurrence advantages as single treatment options in appropriate node status groups.
Histologic Analysis
Of the 465 total cases, 395 could be confidently assigned to one of the categories in the Working Formulation ( Table 1 ). The exclusion of the 67 cases without enough data to assign tumor classification is not random and probably does introduce an undesirable but unavoidable bias in the frequency of these categories.
Of the 395 cases that could be well characterized, 247 (61.9%) fell into the diffuse, large cell, nonimmunoblastic category, and an additional 32 (8%) were in the large cell immunoblastic category. This frequency of large cell lymphomas is common in most studies. 6, 7 Burkitt's lymphoma or morphologically similar tumors accounted for 23 cases (5.8%). Only 6 cases (1.5%) of lymphoblastic lymphoma were present, 3 of which were identified as being of T-cell origin.
At the other end of the spectrum, 18 cases (4.5%) were identified as small lymphocytic lymphoma, with or without plasmacytoid differentiation. In only 35 cases (8.8%) was a follicular pattern specified, although it appeared that this information may simply have been omitted in some reports. Of these follicular PBL cases, 13 (3.3%) were predominantly small cell, 13 (3.3%) were mixed large and small cell type, and 9 (2.2%) were predominantly large cell.
There were 15 cases (3.7%) of diffuse small cleaved cell tumors (probably underestimated in view of the nature of cases that could not be reliably translated), and 19 cases (4.8%) were identified as diffuse, mixed large and small cell type. Four cases of Hodgkin disease were included. However, the selection criteria identified in many of the papers would have excluded Hodgkin disease, and our sample probably does not represent the true incidence of Hodgkin disease presenting as a breast lesion.
Classification according to the World Health Organization could be accomplished in only 213 cases due to lack of information, thereby excluding more than half of the data base for any analysis using this classification. A total of 102 cases (47.9%) were specifically identified as diffuse, large B-cell lymphomas. Thirty-three cases (15.5%) were follicular lymphomas, 26 (12.2%) were identified as MALT lymphoma, and 22 (10.3%) as Burkitt or Burkitt-like tumors. In all, 195 (91.5%) cases were identified as being of B-cell origin and only 14 (6.6%) as being of T-cell origin, with the 4 cases of Hodgkin disease accounting for the remainder. 
DISCUSSION
The definition of PBL, established by Weisman and Liao in 1972, limits this unique condition to stage I and stage II lymphomas for the purpose of excluding lymphoma originating at other sites. More than 200 articles have appeared over the decades concerning this uncommon disease. Reports include case studies, institutional reviews, and summary articles with literature review. PBL is uncommon enough that a single publication may include multiple cases collected over many years or decades managed with a variety of treatments. Our study is similar in concept to a meta-analytic review, but instead of combining statistical findings from multiple studies, individual patient information was abstracted. 8 We required sufficient individual information for evaluation of the patient's presentation as PBL, in addition to treatment and outcome data. We found most reports of PBL share a similar pattern of descriptive information. We thought this approach was appropriate for analysis of PBL, as this breast malignancy is too rare for a single institution prospective trial, yet it is common enough for the publication of many detailed case reports and institutional experience articles. Individual patient therapy for PBL has varied widely, including chemotherapy and radiation therapy in addition to surgical procedures ranging from biopsy to radical mastectomy. In general, chemotherapy and/or radiation therapy have emerged as the most common treatments for PBL, with surgery used for tissue diagnosis and classification of the tumor. However, despite the frequently stated opinion that chemotherapy without mastectomy represents the mainstay of treatment of PBL, published reports frequently include patients whose treatment included mastectomy. 1,9 -17 Our study found that mastectomy offered no benefit in survival or recurrence risk. Several authors argue that mastectomy is not necessary based on individual and institutional experience, and this position is supported by treatment experience for lymphomas of other organ sites. 3,18 -22 Most advocate systemic chemotherapy as the proper treatment. Other authors have reported that mastectomy was included for PBL due to a breast lesion being misdiagnosed preoperatively as poorly differentiated carcinoma. 10 Treatment selection for PBL using radiation therapy and/or chemotherapy also varies in the literature. No consensus of opinion exists as to when each or both of these therapies should be used. Wong et al found improved outcomes in PBL by the use of radiation therapy in combination with chemotherapy. 23 Others report a similar experience and emphasize the use of radiation therapy. 11 Dao et al 3 suggest small PBL tumors should undergo wide local excision with radiation therapy as primary treatment. They recommended that high-grade lesions and those with axillary involvement should have combination radiotherapy and chemotherapy, suggesting that radical operations are not indicated in most cases. 3 The most common chemotherapy agents used in PBL have been those in the CHOP regimen. Many of the articles reviewed for this current report used this or a similar form of chemotherapy, although the majority of reports described chemotherapy without specific agent identification. Strategies to minimize cardiac toxicity risks associated with doxorubicin-containing combination regimens by using adjuvant radiation therapy have been reported for non-Hodgkin lymphoma of sites other than breast and may be important. 24 Hennessy and Valero reviewed similar risks and treatment strategies associated with anthracycline-taxane combination therapy for metastatic breast cancer. 25 Babovic et al also recognized the importance of radiation therapy for controlling local disease and allowing shorter treatment with chemotherapy with reduction of cardiac risk. 20 Miller et al reported improved survival in non-Hodgkin's lymphoma when adding radiation therapy to 3 cycles of CHOP as opposed to 8 cycles of CHOP alone. 24 Survival rates reported in PBL vary widely. Some authors have reported 5-year survival rates up to 89% and 50% for stages I and II, respectively. 12, 26 Others have reported PBL to have a poor prognosis, irrespective of treatment with median survival time as low as 12 months. 10, 13, 27 Five-year survival rates in our study were 78% for stage I patients whose treatment included radiation therapy with or without chemo-therapy and 49% for stage II patients whose treatment included chemotherapy with or without radiation therapy. We found right-and left-sided PBLs were evenly distributed, although some papers have reported a higher incidence of PBL on the right side. 16, 28 As opposed to our study, other authors found age to be an independent predictor of outcome. 17, 26 A high incidence of central nervous system involvement with PBL was noted by Gholam et al. 29 They recommended that aggressive forms of PBL should have central nervous system prophylaxis administered, as have other authors. 22, 27 Ribrag et al also reported a high incidence of central nervous system relapse in extranodal lymphomas and suggest that central nervous system prophylaxis should be included in therapy for localized PBL. 21 More recently, rituximab (monoclonal antibody) has been added to some chemotherapy regimens for B-cell lymphomas. Significant outcome improvement has been noted in initial use. However, to our knowledge, rituximab has not been described in the treatment of PBL. Immunotherapy has been used for B-cell lymphomas in combination with chemotherapy or radiation therapy. 30 We found no report or reference to sentinel node evaluation in PBL, although in light of the findings in this study regarding node status and treatment selection, a sentinel node biopsy might influence treatment decisions in clinically node-negative patients. In selected breast cancer patients, image guided needle biopsy of suspicious axillary lymph nodes identified by ultrasound has been helpful. However, in lymphoma, needle biopsy often leaves uncertainty regarding specific classification or even diagnosis. Ultrasound might be useful in evaluating the axilla for PBL patients by targeting suspicious lymph nodes for removal and could be coupled with sentinel node biopsy. Few authors mentioned estrogen receptor analysis with PBL, and no application has emerged, although estrogen receptor assay has been reported rarely as positive. 17 The Ann Arbor staging system and international prognostic index have been reliable predictors in extranodal lymphoma outcomes. 31 As in our paper, other reports have found histologic tumor grading and stage to predict outcome for PBL. 1, 3, 19, 29 Histologic grading has been used to aide in determining appropriate chemotherapy, radiation therapy, or combination treatment. 3, 12, 19, 22, 29 
Clinical Observations
Clinicians should be aware of the important differences in physical examination and imaging between PBL and the much more common breast carcinoma. 32, 33 PBL is rarely discovered by screening mammography. 19 When diagnostic mammography is obtained, PBL often appears as a welldefined mass with benign characteristics. These tumors usually have smooth margins with a homogeneous appearance. Other signs of breast malignancy are not commonly found by mammography. Calcifications, spiculation, or distortion of surrounding tissue are usually absent. Ultrasound will most often mistakenly suggest a benign, well-defined lesion. 16, 34 PBL frequently appears as a hypoechoic lesion by ultrasound, without shadowing or enhancement, although some reports found more suspicious characteristics. 35 Jackson et al reported nonspecific abnormalities with PBL in both ultrasound and mammography and recognized the need for both studies. 16 Bilateral breast lymphoma at the time of diagnosis is not rare and has been reported in up to 30% of patients. 14 On physical examination, PBL frequently appears as a benign or less suspicious lesion. 32, 33 PBL usually presents as a single palpable mass that is mobile and nontender. Palpable ipsilateral lymphadenopathy has been noted in 30% to 70% of cases. Multifocal tumors or diffuse breast involvement have also been reported. 34 Clinical signs of advanced breast malignancy are rare, such as inflammatory changes, nipple involvement, skin retraction, or tumor fixation. 17 Right or left breast dominance of these lesions has been debated in the past but was not found in this study.
CONCLUSION
A database was compiled of patient information from all published primary breast lymphoma reports during the last 33 years where individual patient treatment and outcome data were included in the publication. A total of 465 patients were identified that met these criteria. This study found that mastectomy offered no benefit in the treatment of primary breast lymphoma. Treatment that included radiation therapy in stage I patients (node negative) showed benefit in both survival (P ϭ 0.002) and recurrence rates. Treatment that included chemotherapy in stage II patients (node positive) showed benefit in both survival (P ϭ 0.001) and recurrence rates. Data regarding combined radiation and chemotherapy were equivocal due to small sample sizes, but together they likely had the same survival and recurrence advantages as single treatment options in appropriate node status groups. Comparison of survival characteristics that do not account for node status may lead to erroneous conclusions. Histologic tumor grade predicted survival. Patient survival was unchanged in cases published before or after 1995.
